Philip Portoghese, PhD
Co-Founder and Principal Scientific Advisor
Professor Portoghese is a world-renowned medicinal chemist, co-founder of Blue Therapeutics and...
Michio Painter, PhD
Co-Founder and Chief Executive Officer
Michio spent nearly a decade advancing basic biological research at Harvard University...
Ajay Yekkirala, PhD
Co-Founder and Chief Scientific Officer
Ajay is responsible for scientific and experimental oversight at Blue with over 10 years of research...
David Roberson, PhD, MBA
Co-Founder and Chief Operating Officer
Before co-founding Blue Therapeutics, David spent 8 years developing novel analgesics, anti-pruritics...

Alleviating Pain is our passion

We are an early stage drug development company pursuing better treatment options for patients in pain. Our goal at Blue Therapeutics is to break the chain of opioid addiction by creating highly effective, non-addictive painkillers.

Using promising new pain relief targets identified by our team, we are developing non-narcotic small molecules with potent analgesic properties that lack the unwanted side effects of opioid painkillers, especially addictive potential.

We are advancing our lead compound, BLUE-181, through industry standard safety studies to determine its suitability for clinical trials. Our nonclinical studies have found this remarkable molecule to reduce pain measures more potently than morphine, while lacking signs of abuse potential.

LEARN MORE ABOUT BLUE
PRESS & INVESTOR INFO